StreetInsider.com News Articles

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 14:43:40 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices

Workflow extends NULISA into longitudinal, decentralized, and population-scale research

FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 14:43:40 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices

Workflow extends NULISA into longitudinal, decentralized, and population-scale research

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 08:11:00 -0400

NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research

Fremont, CA, June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood

Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics

Tue, 02 Jun 2026 08:11:00 -0400

BofA Securities Resumes Alamar Biosciences (ALMR) at Neutral

Tue, 12 May 2026 06:22:28 -0400

BofA Securities analyst Michael Ryskin resumes coverage on Alamar Biosciences (NASDAQ: ALMR) with a Neutral rating and a price target of $27.00.

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click here.

Shares of Alamar Biosciences closed at $23.88 yesterday.

Leerink Partners Starts Alamar Biosciences (ALMR) at Outperform

Tue, 12 May 2026 06:08:03 -0400

Leerink Partners analyst Punee initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Alamar Biosciences click here. For more ratings news on Alamar Biosciences click here.

Shares of Alamar Biosciences closed at $23.88 yesterday.

TD Cowen Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 05:29:57 -0400

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $30.00.

The analyst comments "We initiate on ALMR at Buy w/a $30 PT (26% upside). Its NULISA chemistry & easy-to-use, robust Argo platform offer a one-two combo that is generating material enthusiasm at leading Pharma and A&G proteomics customers. NULISA is ultra-sensitive & can scale from 1 protein into the 100s, enabling use across R&D & diagnostics. Sales are set to more than double ('25 to '27) & grow at a 40% CAGR to '30."

For an analyst ratings summary and

TD Cowen Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 05:29:57 -0400

TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $30.00.

For an analyst ratings summary and

JPMorgan Starts Alamar Biosciences (ALMR) at Overweight

Tue, 12 May 2026 03:16:48 -0400

JPMorgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Overweight rating and a price target of $30.00.

The analyst comments: “We are initiating coverage of Alamar Biosciences (ALMR) with an Overweight rating and a DCF-derived December 2026 PT of $30. ALMR is a proteomics platform company whose proprietary Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) chemistry, run on the ARGO instrument, is creating a new gold standard in protein measurement by combining ultra-high sensitivity with flexible multiplexing and full automation. ALMR has seen robust early adoption in the RUO setting, which is poised for sustainable future growth, while

JPMorgan Starts Alamar Biosciences (ALMR) at Overweight

Tue, 12 May 2026 03:16:48 -0400

JPMorgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Overweight rating and a price target of $30.00.

Stifel Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 01:06:26 -0400

Stifel analyst Daniel Arias initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $28.00.

The analyst comments: “We are initiating coverage of Alamar Biosciences (ALMR) with a Buy rating and a 12-month TP of $28. Alamar is an emerging multiplex proteomics player that has seen rapid adoption of its ARGO platform in a short period of time, thanks to performance and workflow advantages that have them positioned as best in-class. This yielded almost 200% growth last year. Looking ahead, we expect ramping usage in key fields (neuroscience, in particular) that should drive near/mid-term strength

Stifel Starts Alamar Biosciences (ALMR) at Buy

Tue, 12 May 2026 01:06:26 -0400

Stifel analyst Daniel Arias initiates coverage on Alamar Biosciences (NASDAQ: ALMR) with a Buy rating and a price target of $28.00.

Form 10-Q Alamar Biosciences, Inc. For: Mar 31

Fri, 08 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260508/26458321.html

Form 8-K Alamar Biosciences, Inc. For: May 08

Fri, 08 May 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260508/26458032.html

Alamar Biosciences Reports First Quarter 2026 Financial Results

Fri, 08 May 2026 08:00:00 -0400

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.

Recent Highlights

Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.
Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.
Raised approximately $220 million in gross proceeds from our initial public offering in April

Alamar Biosciences Reports First Quarter 2026 Financial Results

Fri, 08 May 2026 08:00:00 -0400

Recent Highlights

Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.
Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.
Raised approximately $220 million in gross proceeds from our initial public offering in April

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

Tue, 05 May 2026 16:05:00 -0400

FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada.

Alamar Biosciences’ management is scheduled to present on Tuesday, May 12, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the “Investors” section of the company website at investors.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar is a life sciences

Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference

Tue, 05 May 2026 16:05:00 -0400

About Alamar Biosciences, Inc.

Alamar is a life sciences

Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026

Thu, 30 Apr 2026 16:05:00 -0400

FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026.

Alamar Biosciences plans to host and webcast its first earnings conference call as a public company in August 2026 to report second quarter 2026 financial results.

About Alamar Biosciences, Inc.

Alamar is a life sciences company dedicated to powering Precision Proteomics to enable the earliest detection of disease. Leveraging its

Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026

Thu, 30 Apr 2026 16:05:00 -0400

Alamar Biosciences plans to host and webcast its first earnings conference call as a public company in August 2026 to report second quarter 2026 financial results.

About Alamar Biosciences, Inc.

Alamar is a life sciences company dedicated to powering Precision Proteomics to enable the earliest detection of disease. Leveraging its

Form SCHEDULE 13D Alamar Biosciences, Inc. Filed by: Illumina Innovation Fund II, L.P.

Thu, 23 Apr 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260423/26360116.html

Form SCHEDULE 13D Alamar Biosciences, Inc. Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Thu, 23 Apr 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260423/26357991.html

Form 4 Alamar Biosciences, Inc. For: Apr 20 Filed by: Qiming Venture Partners VIII Investments, LLC

Wed, 22 Apr 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260422/26351702.html

Form EFFECT Alamar Biosciences, Inc.

Tue, 21 Apr 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260421/26339329.html

Form 4 Alamar Biosciences, Inc. For: Apr 16 Filed by: Naclerio Nicholas

Mon, 20 Apr 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260420/26338415.html